Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: An observational study

Epilepsia

Volumn 50, Issue 8, 2009, Pages 1910-1919

  Cho, Yang Je ^a   Heo, Kyoung ^a   Kim, Won Joo ^a   Jang, Sang Hyun ^a   Jung, Yo Han ^a   Ye, Byoung Seok ^a   Song, Dong Beom ^a   In Lee, Byung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Efficacy; Epilepsy; Refractory; Tolerability; Topiramate

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADD ON THERAPY; ADULT; ANOREXIA; ARTICLE; COGNITIVE DEFECT; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; GASTROINTESTINAL DISEASE; HUMAN; KAPLAN MEIER METHOD; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; EPILEPSIES, PARTIAL; FEMALE; FRUCTOSE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OBSERVATION; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 68149107592     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2009.02177.x     Document Type: Article

References (24)

1. Abou-Khalil B 2000) Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group. Epilepsia 41 (suppl 1 S72 S76.
2. Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, Reife R, Kramer L, Pledger G, Karim R 1996) Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 37 : 539 543. (Pubitemid 26169188)
3. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B 2001) Early development of intractable epilepsy in children: a prospective study. Neurology 56 : 1445 1452.
4. Berg AT, Kelly MM 2006) Defining intractability: comparisons among published definitions. Epilepsia 47 : 431 436.
5. Bootsma HP, Coolen F, Aldenkamp AP, Arends J, Diepman L, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M 2004) Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 5 : 380 387.
6. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA 2007) Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 62 : 382 389.
7. Commission on Classification and Terminology of the International League Against Epilepsy 1989) Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30 : 389 399.
8. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, Karim RM 1996) Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 46 : 1684 1690.
9. Giannakodimos ST, Georgiadis G, Tsounis ST, Triantafillou N, Kimiskidis V, Giatas K, Karlovasitou A, Mitsikostas DD, Thodi E, Polychronopoulos P, Ramopoulos N, Michailidis K, Michalis N, Garganis K, Gatzonis ST, Balogiannis ST, Kazis AR, Milonas J, Van Oene JC 2005) Add-on topiramate in the treatment of refractory partial-onset epilepsy: clinical experience of outpatient epilepsy clinics from 11 general hospitals. Seizure 14 : 396 402.
10. Korean Topiramate Study Group 1999) Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group. Epilepsia 40 : 1767 1774.
11. Krakow K, Lengler U, Rettig K, Schreiner A, Schauble B 2007) Topiramate in add-on therapy: results from an open-label, observational study. Seizure 16 : 593 600.
12. Lee BI, Heo K, Kim JS, Kim OJ, Park SA, Lim SR, Kim DI, Yoon PH, Kim DK 2002) Syndromic diagnosis at the epilepsy clinic: role of MRI in lobar epilepsies. Epilepsia 43 : 496 504.
13. Lhatoo SD, Wong IC, Sander JW 2000) Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 41 : 338 341.
14. Luciano AL, Shorvon SD 2007) Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 62 : 375 381.
15. Mula M, Trimble MR, Lhatoo SD, Sander JW 2003) Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44 : 659 663. (Pubitemid 36554633)
16. Peltola J, Peltola M, Auvinen A, Raitanen J, Fallah M, Keranen T 2009) Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study. Acta Neurol Scand 119 : 55 60.
17. Perucca E 1997) A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 35 : 241 256.
18. Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, Karim R 1996) Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 46 : 1678 1683. (Pubitemid 26185792)
19. Reife R, Pledger G, Wu SC 2000) Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 41 (suppl 1 66 71.
20. Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R, Pledger G, Karim R 1996) Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 25 : 217 224. (Pubitemid 26394543)
21. Simister RJ, Sander JW, Koepp MJ 2007) Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy Behav 10 : 336 339.
22. Stephen LJ, Sills GJ, Brodie MJ 2000) Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 41 : 977 980.
23. Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, Dam M, Reife R, Pledger G, Karim R 1996) Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 37 : 763 768. (Pubitemid 26276946)
24. Torta R, Keller R 1999) Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 40 (suppl 10 2 20.